Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.

ABSTRACT:

Background

Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular death overall, in those with and without a baseline history of HF, and in other participant subgroups.

Methods

The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) enrolled 10 142 participants with type 2 diabetes mellitus and high cardiovascular risk. Participants were randomly assigned to canagliflozin or placebo and followed for a mean of 188 weeks. The primary end point for these analyses was adjudicated cardiovascular death or hospitalized HF.

Results

Participants with a history of HF at baseline (14.4%) were more frequently women, white, and hypertensive and had a histo

SUBMITTER: Radholm K 

PROVIDER: S-EPMC6075881 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature